JMP Securities Reiterates Market Outperform on Benitec Biopharma, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on Benitec Biopharma (NASDAQ:BNTC) and maintained a $4 price target.
May 18, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst Silvan Tuerkcan reiterated a Market Outperform rating on Benitec Biopharma (NASDAQ:BNTC) and maintained a $4 price target.
The reiteration of the Market Outperform rating and maintenance of the $4 price target by JMP Securities analyst Silvan Tuerkcan indicates a positive outlook for Benitec Biopharma. This news is likely to have a positive short-term impact on BNTC's stock price as it shows confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100